| Aldosterone esters and the heart. | |
| | |
MedLine Citation:
|
PMID: 11411757 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
There are clinical and experimental situations in which symptoms of mineralocorticoid excess are remediable with mineralocorticoid receptor antagonist treatment, in spite of paradoxically low levels of plasma renin and aldosterone. Several decades ago, a factor isolated from the heart was described that had mineralocorticoid properties like those of aldosterone, but much more potent. It was thought to be similar to aldosterone-18-monoacetate or -21-monoacetate, acetyl derivatives of aldosterone that are very rapidly hydrolyzed in the circulation. In our efforts to confirm and extend these observations, we extracted rat hearts and plasma harvested in a manner that would minimize hydrolysis. The product was subjected to several forms of TLC and HPLC and compared to several acetylated derivatives of aldosterone standards. We found that 68% of the aldosterone extracted from fresh myocardium corresponded to an aldosterone derivative that migrates at the same rate as aldosterone-20-monoacetate. The identity of this compound awaits definitive analysis. Tritiated aldosterone-21-monoacetate hydrolyzed to form aldosterone very rapidly; negligible monoacetate remained in blood left at 37 degrees C for 5 min or in hearts left at room temperature for 30 min. Regulation of aldosterone production serves the requirements of fluid and electrolyte homeostasis provided by transport epithelia, primarily that of the kidney. Nonepithelial actions of aldosterone would be freed of these regulatory constraints if the formation of a more potent derivative of the parent compound to which it is almost immediately hydrolyzed in the circulation were regulated within the nonepithelial target tissues. |
| | |
Authors:
|
C E Gomez-Sanchez; M F Foecking; E P Gomez-Sanchez |
Related Documents
:
|
20675957 - New approaches to blockade of the renin-angiotensin-aldosterone system: mineralocortico... 16208147 - Primary hyperaldosteronism: a frequent cause of residual hypertension after successful ... 19895757 - Aldosterone and cardiovascular risk. 219037 - The adrenal receptor for angiotensin ii is altered in essential hypertension. 17003897 - Protein unfolding, amyloid fibril formation and configurational energy landscapes under... 10021957 - Clonidine premedication modifies responses to adrenoceptor agonists and baroreflex sens... |
Publication Detail:
|
Type: In Vitro; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: American journal of hypertension Volume: 14 ISSN: 0895-7061 ISO Abbreviation: Am. J. Hypertens. Publication Date: 2001 Jun |
Date Detail:
|
Created Date: 2001-06-19 Completed Date: 2001-12-04 Revised Date: 2009-02-24 |
Medline Journal Info:
|
Nlm Unique ID: 8803676 Medline TA: Am J Hypertens Country: United States |
Other Details:
|
Languages: eng Pagination: 200S-205S Citation Subset: IM |
Affiliation:
|
Division of Endocrinology, Montgomery VA Medical Center, The University of Mississippi Medical Center, Jackson 39216-4505, USA. cgomez-sanchez@medicine.umsmed.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aldosterone
/
analogs & derivatives*,
metabolism* Animals Blood / metabolism Chromatography, High Pressure Liquid Chromatography, Thin Layer Enzyme-Linked Immunosorbent Assay Esters Hydrolysis Myocardium / metabolism* Radioimmunoassay Rats Rats, Sprague-Dawley |
| Grant Support | |
ID/Acronym/Agency:
|
HL-27255/HL/NHLBI NIH HHS; HL-27737/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Esters; 0/aldosterone-20-acetate; 297-91-6/aldosterone-21-acetate; 52-39-1/Aldosterone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Fibrosis and ischemia: the real risks in hypertensive heart disease.
Next Document: Are low intakes of calcium and potassium important causes of cardiovascular disease?